2. Krivoborodov G.G., Mazo E.B. Overactive bladder. M.: Veche, 2003. 392 p. Russian (Кривобородов Г.Г., Мазо Е.Б. Гиперактивный мочевой пузырь. М.: Вече, 2003. 392 с.).

3. Milsom I., Abrams P., Cardozo L. et al. How wide-spread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.

4. Chapple C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006; 49:651.

5. Sexton C.C., Coyne K.S., Kopp Z.S. et al. The overlap of storage, voiding and postmicturition symptoms and impli- cations for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 12–23.

6. Lopatkin N.A. Guide to urology in 3 volumes. M.: Meditsina. 1998. Russian (Лопаткин Н.А. Руководство по урологии в 3 т. М.: Медицина. 1998).

7. Osipov I.B. Reconstructive surgery for bladder exstrophy in children: Methodological recommendations. SPb.: SPbGPMA, 1995. 28 s. Russian (Осипов И.Б. Реконструктивно-пластические операции при экстрофии мочевого пузыря у детей: Методические рекомендации. СПб.: СПбГПМА, 1995. 28 с.).

8. Lopatkin N.A., Pugachev A.G. Pediatric surgery. Rukovodstvo. M.: Meditsina. 1986. 496 p. Russian (Лопаткин Н.А., Пугачев А.Г. Детская хирургия. Руководство. М.: Медицина. 1986. 496 с.).

9. Dzhavad-Zade M.D. Derzhavin V.M. Neurogenic dysfunction of the urinary bladder. M. «Meditsina», 1989. Р. 101–137, 384. Russian (Джавад-Заде М.Д., Державин В.М. Нейрогенные дисфункции мочевого пузыря. М.: Медицина, 1989. С. 101–137, 384).

10. O’Leary Michael P. Симптомы нижних мочевых путей/Доброкачественная гиперплазия простаты: поддержание контроля над симптомами и предупреждение осложнений. Приложение к журналу «Урология» (UROLOGY). 2003;62(3А).

11. Roehrborn C.G., Mc Connel J., Barry M.J. et al. Guideline on the management of benign prostatic hypertrophy. AUA.

12. Tanaka Y. et al. Clin Exp Pharmacol Physiol 2005; 32(7): 503–514.

13. Ahlquist R.P. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586–600.

14. De Groat W.C., Saum W.R. J Physiol 1972; 220: 297–314.

15. Emorine L.J. et al. Science 1989;245:1118–1121.

16. Fujimura T. et al. J Urol 1999; 161: 680–685.

17. Yamaguchi O. Urology 2002; 59(5 Suppl 1): 25–29.

18. Andersson K.-E., Wein A.J. In: Wein AJ (Ed). Campbell-Walsh Urology (10th ed). Philadelphia, PA: Elsevier Saunders, 2012.

19. Ouslander J.G. N Engl J Med 2004; 350: 786–799.

20. Abdel-Khalek M., Nabieh A., Ibrahiem E. Do muscarinic receptors of the prostate have a significant role in the pathophysiology of bladder outlet obstruction? Phase 1 (in vitro) study. European Urology Supplements, Volume 5, issue 2 (April, 2006). Р. 120.

21. Restorick J., Mundy A.M. The Density of Cholinergic and Alpha and Beta Adrenergic Receptors in the Normal and Hyper-reflexic Human Detrusor. BJU Int. 1989;63(1):32–35.

22. Rohner T. Changes in Adrenergic Receptors in Bladder Outlet Obstruction (Benign prostatic hypertrophy. Edited by Frank Hinman, Jr. by Springer-Verlag New York Inc). 1983. Р. 410–413.

23. Lepor H. Pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Rev in Urol. 2004;6 (Suppl. 9):310.

24. Abrams P.H., Griffiths D.J. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br. J. Urol. 1979;51:129–134.

25. Knutson T., Edlung C., Fall M., Dahlstrand C. BPH with coexisting overactive bladder dysfunction – an everyday urological dilemma. Neurourol Urodyn. 2001;20:237–247.

26. Hashim H., Abrams P. Bladder outlet obstruction, bladder contractility and detrusor overactivity: is there a link. 6th International consultation on new developments in prostate cancer and prostate diseases. June 24–27, 2005, Paris, France. Abst. 29.

27. Abrams P.H., Farrar D.J., Turner-Warwick R.T., Whiteside C.G., Feneley R.C. The results of prostatectomy: A symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121:640–642.

28. Ameda K., Koyanagi T., Taniguchi K., Matsuno T. The relevance of preoperative cystometrography in patients with benign prostatic hyperplasia: correlating the findings with clinical features and outcome after prostatectomy. J Urol. 1994;152:443–447.

29. Vishnevskii A.E. New aspects of the pathogenesis of voiding dysfunction in benign prostatic hyperplasia. Lechashchii vrach. 2000;11. Russian (Вишневский А.Е. Новые аспекты патогенеза расстройств мочеиспускания при доброкачественной гиперплазии простаты. Лечащий врач. 2000;11).

30. Holm N.R., Horn T., Hald T. Detrusor in ageing and obstruction. Scand J Urol Nephrol. 1995;29(1):45–49.

31. Sibley G.N. Physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol. 1987; 60: 332–336.

32. Watson N., Reddy H., Eglen R.M. Pharmacological characterization of the muscarinic receptors mediating contraction of canine saphenous vein. J. Auton. Pharmacol. 1995;15:437–441.

33. Gadzhieva Z.K. Urodynamic studies in the diagnosis and treatment of urinary disorders. Dr.Med.Sci. Thesis. M., 2009. 369 p. Russian (Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Автореф. дисс. д.м.н. М., 2009. 369 с.).

34. Pytel’ Yu.A., Vorkunov I.Ya. Study of renal function in patients with prostate adenoma with radioisotope renography. Urologiya i nefrologiya. 1965;6:11–18. Russian (Пытель Ю.А., Воркунов И.Я. Исследование функции почек у больных аденомой предстательной железы радиоизотопной ренографией. Урология и нефрология. 1965;6:11–18).

35. van Dijk M.M., de la Rosette J.J.M.C.H., Michel M.C. Tamsulosin – modified-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy. 2006;3:237–246.

36. Nickel J.C., Sander S., Moon T.D. Ameta-analysis of the vascular-related safety profi le and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008; 62:1547–1559.

37. Michel M.C., Vrydag W. α1-, α2- and β-Adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147: 88–119.

38. Blaivas J., Marks B., Weiss J., Panagoupolos G., Somaroo C. Differential diagnosis of overactive bladder in men. J Urol. 182: 2814–2817.

39. Gadzhieva Z.K. / Ed. Yu.G. Alyaev. Voiding dysfunction (seriya – Biblioteka vracha-spetsialista). M.: Geotar-Media. 2010. 176 p. Russian (Гаджиева З.К. Под ред. Ю.Г. Аляева. Нарушения мочеиспускания (серия – Библиотека врача-специалиста). М.: Гэотар-Медиа. 2010. 176 с.).

40. Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn. 1985;4:317.

41. Andersson K.E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev. 1993;45:253.

42. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., Sasamata M. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol. 2004;492(2–3):243–250.

43. Chu F. et al. Current therapeutic research. 2009;70(6):405–420.

44. Wehling M., Burkhardt H., Kuhn-Thiel A., Pazan F., Throm C., Weiss C., Frohnhofen H. VALFORTA: a randomized trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing Jan 18, 2016. Doi: 10.1093/ageing/afv200

45. Lokshin K.L., Tangriberganov M.R., Gadzhieva Z.K. Modern possibilities of drug therapy of patient with persisting irritative bladder symptoms after TUR for BPH. Effektivnaya Farmakoterapiya. Urologiya i Nefrologiya. 2012;1. Russian (Локшин К.Л., Тангриберганов М.Р., Гаджиева З.К. Современные возможности медикаментозной терапии при сохранении ирритативных симптомов после ТУР ДГПЖ. Эффективная Фармакотерапия. Урология и Нефрология. 2012;1).

46. Tangriberganov M.R. Features of treatment of benign prostatic hyperplasia in combination with clinical symptoms of overactive bladder. Ph.D. Thesis. M., 2012. 25 p. Russian (Тангриберганов М.Р. Особенности лечения доброкачественной гиперплазии предстательной железы в сочетании с клиническими симптомами гиперактивного мочевого пузыря. Автореф. дисс. канд. мед. наук. М., 2012. 25 с.).

47. Badhiwala N., Kuxhausen A., Vetter J. et al. Use of additional therapy for benign prostatic hyperplasia after TURP and laser vaporization. J Urol. 2015;193:93–94.

48. Herrera-Muñoz J.A. et al. Incidence of and factors associated with the use of medications and surgical retreatment after transurethral resection of the prostate. Rev Mex Urol. 2016;76(3):149–153.

49. Oelke M., Bachmann A., Descazeaud A. et al. EAU guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) 2012.

50. Mazo E.B. Krivoborodov G.G. Kozyrev S.V. The use of α-blockers and cholinolytics in patients with benign prostatic hyperplasia and overactive bladder. RMZh. 2007;12:1016. Russian (Мазо Е.Б. Кривобородов Г.Г. Козырев С.В. Применение α-блокаторов и холинолитиков у больных доброкачественной гиперплазией простаты и гиперактивным мочевым пузырем. РМЖ. 2007;12:1016).

51. Yamada S.T., Oshima H. et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999;12:525–536.

52. Athanasopoulos A., Gyftopoulos K., Giannitsas K., Fisfis J., Perimenis P., Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253–2256.

53. Lee K.S., Kim D.Y., Kim J.C. et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. 2004 ICS annual meeting

54. Lee K.S., Choo M.S., Kim D.Y. et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334–1338.

55. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28.

56. Kaplan S.A., McCammon K., Fincher R., Fakhoury A., He W. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol. 2009;182:2825–2830.

57. MacDiarmid S.A., Peters K.M., Chen A. et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo- controlled study. Mayo Clin Proc. 2008;83:1002–1058.

58. Chapple C., Herschorn S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with -blockers. Eur Urol. 2009;56:534–541.

59. Yamaguchi O., Kakizaki H., Homma Y. et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms-ASSIST, randomized controlled study. Urology. 2011;78:126–133.

60. Kaplan S.A., Roehrborn C.G., Gong J., Sun F., Guan Z. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int. 2012;109:1831–1840.

61. Lee S.H., Chung B.H., Kim S.J. et al. Initial combined treatment with anticholinergics and -blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multicenter, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14:320–325.

62. Van Kerrebroeck P., Haab F., Angulo J.C. et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN) Eur Urol. 2013;64(3):398–407.

63. Van Kerrebroeck P., Chapple C., Drogendijk T. et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003–1012.

64. Drake M., Chapple C., van Kerrebroeck P. et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol. 2012 EAU Abstracts #746.H.